122 / 154
448
metastases in trials of the International Breast Cancer Study
Group (IBCSG). Ann Oncol 2006;17:935–944.
85. Musolino A, Ciccolallo L, Panebianco M, et al. Multifactorial
central nervous system recurrence susceptibility in patients
with HER2-positive breast cancer: epidemiological and clinical
data from a population-based cancer registry study. Cancer
2011;117:1837–46.
86. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior
of breast cancer subtypes. J Clin Oncol 2010;28:3271–7.
87. Shen Q, Sahin AA, Hess KR, et al. Breast cancer with brain
metastases: clinicopathologic features, survival, and paired
biomarker analysis. Oncologist 2015;20: 466–73.
88. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, et al.
Receptor conversion in distant breast cancer metastases.
Breast Cancer Res 2010;12:R75.
89. Bachmann C, Grischke EM, Fehm T, Staebler A, Schittenhelm
J, Wallwiener D.. CNS metastases of breast cancer show
discordant immunohistochemical phenotype compared to
primary. J Cancer Res Clin Oncol 2013;139: 551–6.
90. Gianni L, Dafni U, Gelber RD, et al. Treatment with
trastuzumab for 1 year after adjuvant chemotherapy in
patients with HER2-positive early breast cancer: a 4-year
follow-up of a randomised controlled trial. Lancet Oncol
2011;12: 236–44.
91. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab
in HER2-positive breast cancer. N Engl J Med 2015;365:1273–
83.
92. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous
system metastases in women who receive trastuzumab-
based therapy for metastatic breast carcinoma. Cancer
2003;97:2972–7.
93. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral
metastases in patients treated with trastuzumab for metastatic
breast cancer. Br J Cancer 2004;91:639–43.
94. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B,
Heinemann V. Characteristics of patients with brain metastases
receiving trastuzumab for HER2 overexpressing metastatic
breast cancer. Breast 2006;15:219–25.
95. Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, eta al.
Incidence, pattern and timing of brain metastases among
patients with advanced breast cancer treatedwith trastuzumab.
Acta Oncol 2006;45:196–201.
96. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol
2000;18:2349–51.
97. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin
Cancer Res 2007;13:1648–55.
98. Lin N, Diéras, V, Paul D, et al. Multicenter phase II study of
lapatinib in patients with brain metastases fromHER2-positive
breast cancer. Clin Cancer Res 2009;15:1452–9.
99. Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-
positive metastatic breast cancer with lapatinib and
capecitabine in the lapatinib expanded access programme,
including efficacy in brain metastases--the UK experience. Br
J Cancer 2010;102:995–1002.
100. Lin NU, Eierman W, Greil R, et al. Randomized phase II study
of lapatinib plus capecitabine or lapatinib plus topotecan for
patients with HER2-positive breast cancer brain metastases.
J Neurooncol 2011;105: 613–20.
101. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus
capecitabine in patients with previously untreated brain
metastases from HER2-positive metastatic breast cancer
(LANDSCAPE): a single-group phase 2 study. Lancet Oncol
2013;14:64–71.
102. Swain SM, Baselga J, Miles D, et al. Incidence of central
nervous system metastases in patients with HER2-positive
metastatic breast cancer treated with pertuzumab,
trastuzumab, and docetaxel: results from the randomized
phase III study CLEOPATRA. Ann Oncol 2014;25:1116–21.
103. Swain SM, Baselga J, Kim SB, et al; CLEOPATRA Study Group.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive
metastatic breast cancer. N Engl J Med 2015;372:724-34.
104. Senda N, Yamaguchi A, Nishimura H, Shiozaki T, Tsuyuki
S. Pertuzumab, trastuzumab and docetaxel reduced the
recurrence of brain metastasis from breast cancer: a case
report. Breast Cancer 2016;23:323-8.
105. Cortes J, Dieras V, Ro J, et al. Afatinib alone or afatinib
plus vinorelbine versus investigator’s choice of treatment
for HER2-positive breast cancer with progressive brain
metastases after trastuzumab, lapatinib, or both (LUX-Breast
3): a randomised, open-label, multicentre, phase 2 trial.
Lancet Oncol 2015;16:1700-10.
106. Freedman RA, Gelman RS, Wefel JS, et al. Translational Breast
Cancer Research Consortium (TBCRC) 022: a phase II trial of
neratinib for patients with human epidermal growth factor
receptor 2-positive breast cancer and brain metastases. J Clin
Oncol 2016;34:945-52.
107. Niikura N, Hayashi N, Masuda N, et al. Treatment outcomes
and prognostic factors for patients with brainmetastases from
breast cancer of each subtype: a multicenter retrospective
analysis. Breast Cancer Res Treat 2014;147:103–12.
108. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN,
Gonzalez-Angulo AM. Survival among women with triple
receptor-negative breast cancer and brain metastases. Ann
Oncol 2009;20:621–7.
109. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, and
Gonzalez-Angulo AM. Incidence of brain metastases as a
first site of recurrence among women with triple receptor-
negative breast cancer. Cancer 2012;118:4652–9.
110. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites
of distant recurrence and clinical outcomes in patients with
metastatic triple-negative breast cancer: high incidence of
central nervous systemmetastases. Cancer 2008;113:2638–
45.
111. Rosner D, Nemoto T, Lane WW. Chemotherapy induces
regression of brain metastases in breast carcinoma. Cancer
1986;58:832–9.
112. Chang AY, Ying XX. Brain Metastases from Breast Cancer and
Response to Treatment with Eribulin: A Case Series. Breast
[REV. MED. CLIN. CONDES - 2017; 28(3) 437-449]